New antibiotic for hospital-acquired pneumonia
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This study tests a new antibiotic called YK-1169 against a standard treatment for pneumonia that develops during a hospital stay or while on a breathing machine. It aims to see if the new drug works just as well or better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You are currently in the hospital with pneumonia that started after being admitted or while on a ventilator.
- You have symptoms like fever, cough, or trouble breathing, and a chest X-ray shows signs of pneumonia.
- You have not taken strong antibiotics for this infection for more than 24 hours in the last 3 days (unless the treatment failed).
- You are not on dialysis, do not have severe kidney problems, and your liver function is within acceptable limits.
- You agree to use effective birth control during the study and for 3 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new antibiotic (BV100) combined with other antibiotics works safely and effectively against serious infections caused by drug-resistant Acinetobacter bacteria. It may offer a treatment option when standard antibiotics are not working.
This trial compares a new antibiotic (BV100 plus low-dose polymyxin B) against a standard treatment for pneumonia caused by a hard-to-treat bacteria (Acinetobacter baumannii). If you have hospital-acquired or ventilator-associated pneumonia and standard antibiotics aren't working, this study may offer a new option.
This study compares an experimental antibiotic called ASK0912 with an approved antibiotic (polymyxin B) in adults with hospital-acquired or ventilator-associated pneumonia. It aims to see if the new drug is as effective and safe as the standard treatment.
This trial tests a combination of two antibiotics (meropenem and pralurbactam) for treating serious infections caused by bacteria that are resistant to many other antibiotics. It may be an option for hospitalized patients with pneumonia, urinary tract infections, abdominal infections, or bloodstream infections.
This study tests an antibiotic called ceftazidime-avibactam for people with serious infections like bloodstream infections or pneumonia that started in the hospital or from a breathing machine. It aims to start treatment quickly after identifying the bacteria.
This trial tests a combination of two antibiotics (meropenem and pralurbactam) to see if they work better than other treatments for people with pneumonia that started in the hospital or from a breathing machine. If you qualify, this study might offer you a new treatment option.
Hear when a new Hospital-acquired Bacterial Pneumonia (HABP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.